Boron Neutron Capture Therapy Followed by Image-Guided Intensity-Modulated Radiotherapy for Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial

Simple Summary Boron neutron capture therapy (BNCT) is a target radiotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) that has been used for recurrent head and neck cancer. To procure better results, the current study designed to combine both as salvage treatment for this challenging problem. For the 14 patients enrolled, a high response rate and low incidence of grade 4 toxicity were seen at follow-up. Further local recurrence was the main cause of failure in spite of the larger radiation volumes and extra dose given with IG-IMRT after BNCT than with BNCT alone. Further revision of this protocol is suggested to improve our results. Abstract Background: This trial investigated the efficacy and safety of salvage boron neutron capture therapy (BNCT) combined with image-guided intensity-modulated radiotherapy (IG-IMRT) for recurrent head and neck cancer after prior radiotherapy (RT). Methods: BNCT was administered using an intravenous boronophenylalanine–fructose complex (500 mg/kg) in a single fraction; multifractionated IG-IMRT was administered 28 days after BNCT. For BNCT, the mucosa served as the dose-limiting organ. For IG-IMRT, the clinical target volume (CTV) and the planning target volume (PTV) were generated according to the post-BNCT gross tumor volume (GTV) with chosen margins. Results: This trial enrolled 14 patients, and 12 patients received combined treatment. The median BNCT average dose for the GTV was 21.6 Gy-Eq, and the median IG-IMRT dose for the PTV was 46.8 Gy/26 fractions. After a median (range) follow-up period of 11.8 (3.6 to 53.2) months, five patients had a complete response and four had a partial response. One patient had grade 4 laryngeal edema; another patient had a grade 4 hemorrhage. Most tumor progression occurred within or adjacent to the CTV. The 1-year overall survival and local progression-free survival rates were 56% and 21%, respectively. Conclusion: Despite the high response rate (64%) of this trial, there was a high incidence of in-field and marginal failure with this approach. Future studies combining BNCT with modalities other than radiation may be tried.

[1]  J. Hatazawa,et al.  Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan(10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Shyh-Jen Wang,et al.  The overview and prospects of BNCT facility at Tsing Hua Open-pool reactor. , 2020, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[3]  K. Chuang,et al.  A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer , 2019, PloS one.

[4]  B. Devnani,et al.  Reirradiation with IMRT for recurrent head and neck cancer: A single-institutional report on disease control, survival, and toxicity. , 2017, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[5]  Willem L. J. Weijs,et al.  Reirradiation of head and neck cancer: Long‐term disease control and toxicity , 2017, Head & neck.

[6]  Yi-Wei Chen,et al.  Fractionated Boron Neutron Capture Therapy in Locally Recurrent Head and Neck Cancer: A Prospective Phase I/II Trial. , 2016, International journal of radiation oncology, biology, physics.

[7]  K. Ono,et al.  Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer , 2013, Journal of radiation research.

[8]  Ji Yoon Kim,et al.  Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy , 2013, Radiation oncology journal.

[9]  Shinji Kawabata,et al.  Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer , 2012, Radiation oncology.

[10]  S. Savolainen,et al.  Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. , 2012, International journal of radiation oncology, biology, physics.

[11]  J. Debus,et al.  Reirradiation with intensity‐modulated radiotherapy in recurrent head and neck cancer , 2011, Head & neck.

[12]  J. Purdy,et al.  Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[13]  F. Hsu,et al.  Verification of the accuracy of BNCT treatment planning system THORplan. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  Adam S Garden,et al.  IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. , 2009, International journal of radiation oncology, biology, physics.

[15]  S. Savolainen,et al.  Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[16]  A. Paetau,et al.  Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine , 2003, Journal of Neuro-Oncology.

[17]  K. Ono,et al.  Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors. , 2006, International journal of radiation oncology, biology, physics.

[18]  K. Ono,et al.  First clinical case of boron neutron capture therapy for head and neck malignancies using 18F‐BPA PET , 2006, Head & neck.

[19]  J. Coderre,et al.  The radiation biology of boron neutron capture therapy. , 1999, Radiation research.

[20]  Y. Mori,et al.  Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. , 1989, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].